surveys (n¼3) were conducted with the manufacturers of the technologies under assessment, focussing on their views of the production and procedures. RESULTS: For all three published assessments the timelines have largely been kept and publication was close to publication of the European Public Assessment Report (EPAR), which facilitated the level of implementation of these assessments at a national level. Authoring agencies of these assessments agreed that the scope should reflect a European perspective, the production process should be simplified, and stakeholder engagement should be increased. The manufacturers of these technologies under assessment were positive about the process and the published reports, but stressed the need for further methodological development and creation of submission requirements and information sharing policy. CONCLUSIONS: EUnetHTA JA3 has an established process to conduct pharmaceutical assessments. While the first three published assessments showed positive experiences from both the HTA and pharmaceutical industry perspective, the need for procedural developments was acknowledged to further strengthen European joint HTA work and their impact at a national level.OBJECTIVES: Health technology assessment (HTA) mainly based on international evidence was introduced in the Romanian pharmaceutical reimbursement system in 2014. Our objective was to assess the current status of HTA implementation and to determine the long-term preferences for development HTA development in Romania. METHODS: We applied the survey template published by Kalo et al (2016) among the participants at the National Conference of Pharmacoeconomics and Health Management. Further targeted sampling among public stakeholders (from regulatory agency and academia) was applied to increase the sample size. RESULTS: 71% of the 48 respondents were from public sector. There are limited training opportunities for HTA in Romania. 61% of the participants advocated the establishment of postgraduate HTA training program in 10 years. Respondents preferred public funding of HTA activities, including both HTA research and critical appraisals of HTA dossiers. Although the initial HTA system was based on international evidence, the majority of respondents would like to make sure that local data is taken into account (46%) or even mandatory (52%). Majority of respondents would extend current decision categories by unmet medical need (77%), therapeutic value (81%) and cost-effectiveness (86%), and would consider the revision of previous reimbursement decisions (93%). 66% of respondents were aware of having a public HTA body, however majority of them (64%) would prefer the involvement of academic institutions. Explicit soft thresholds was the recommended decision method by 70% of respondents. All respondents would invest into patient registries and utilisation of data from payer's databases. The trend of involvement to international joint work should be continued in Romania. CONCLUSIONS: Our results indicated the continuous need to streng...

No abstract

No abstract